Similar Papers

Paper Title
Journal
Date
Author
Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization.
Debra Schaumberg ... Kay Larholt
Therapeutic innovation & regulatory science | VOL. 57
Debra Schaumberg, et. al.Debra Schaumberg ... Kay Larholt
09 Jan 2023
Contributors
-
Interfaces | VOL. 41
--
01 Feb 2011
Contributors
-
Operations Research | VOL. 59
--
01 Oct 2011
Maintaining Warp Speed: Policy Requirements for a Just-in-Time, Capability-Based, Scalable Medical Countermeasure Research and Development Enterprise.
Colin N O'Leary ... Julia Barnes-Weise
Health security | VOL. 21
Colin N O'Leary, et. al.Colin N O'Leary ... Julia Barnes-Weise
18 May 2023
View more papers

More From: Clinical pharmacology and therapeutics

Paper Title
Journal
Date
Author
Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases.
Thandeka V.B Malinga ... David Twesigomwe
Clinical pharmacology and therapeutics | VOL. -
Thandeka V.B Malinga, et. al.Thandeka V.B Malinga ... David Twesigomwe
20 Jan 2025
Methodological Insights on Biomarker-Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency.
Cynthia Huber ... Marcia Rueckbeil
Clinical pharmacology and therapeutics | VOL. -
Cynthia Huber, et. al.Cynthia Huber ... Marcia Rueckbeil
18 Jan 2025
A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence Assessments.
Robert Hopefl ... Lanyan Fang
Clinical pharmacology and therapeutics | VOL. -
Robert Hopefl, et. al.Robert Hopefl ... Lanyan Fang
18 Jan 2025
Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor.
Manthena V S Varma ... Manoli Vourvahis
Clinical pharmacology and therapeutics | VOL. -
Manthena V S Varma, et. al.Manthena V S Varma ... Manoli Vourvahis
14 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.